Eli Lilly (LLY)

963.33
+28.73 (3.07%)
NYSE · Last Trade: May 3rd, 4:50 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Dear Veeva Systems Stock Fans, Mark Your Calendar for May 7
Veeva Systems stock pops following S&P 500 inclusion announcement.
Via Barchart.com · May 1, 2026
Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens Bankruptcybenzinga.com
Major M&A deals this week include: Eli Lilly buys Profluent for $2.2 billion, Lazard buys Campbell Lutyens, FreshRealm bankruptcy.
Via Benzinga · May 1, 2026
Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanentmarketbeat.com
Via MarketBeat · May 1, 2026
There's Another Twist In The Obesity Pills Showdown — And This One Actually Helps Lillyinvestors.com
The prescription data collected for Eli Lilly's new weight-loss pill, Foundayo, is flawed, analysts said Friday.
Via Investor's Business Daily · May 1, 2026
Eli Lilly (NYSE:LLY) Shatters Q1 Expectations with Blowout Earnings Beatchartmill.com
Via Chartmill · April 30, 2026
Why Eli Lilly (LLY) Stock Is Trading Up Today
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.3% in the morning session after the stock continued to rally as the comp...
Via StockStory · May 1, 2026
Viking Therapeutics Faces Timeline Risk—But Upside Could Be Hugemarketbeat.com
Via MarketBeat · May 1, 2026
Eli Lilly Stock Popped on Earnings. America Can’t Get Enough of Its GLP-1s.
Eli Lilly stock jumps on strong Q1 performance numbers, with its GLP-1s leading the chart.
Via Barchart.com · May 1, 2026
LLY Q1 Deep Dive: Obesity Franchise Expansion and Pipeline Investment Drive Outperformance
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 55.5% year on year to $19...
Via StockStory · May 1, 2026
Eli Lilly Capitalizes On Consumers' 'Love Affair' With Weight Loss Drugs: Gary Black Says Valuation 'Still Looks Compelling'benzinga.com
Gary Black calls Eli Lilly's valuation 'compelling' as Q1 earnings soar, driven by the consumer 'love affair' with GLP-1 weight loss drugs.
Via Benzinga · May 1, 2026
Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Todaybenzinga.com
Via Benzinga · April 30, 2026
GLP-1 Sales Continue to Lift Eli Lilly. Does That Make LLY Stock a Buy?
Eli Lilly stock rallies as GLP-1 sales drive a 56% year-on-year increase in Q1 revenue. Jim Cramer recommends buying LLY shares as the weight-loss addressable market is truly huge.
Via Barchart.com · April 30, 2026
Thursday's session: top gainers and losers in the S&P500 indexchartmill.com
Via Chartmill · April 30, 2026
In today's session, there are S&P500 stocks with remarkable trading volume.chartmill.com
Via Chartmill · April 30, 2026
Eli Lilly (LLY) Q1 2026 Earnings Transcriptfool.com
Eli Lilly (LLY) Q1 2026 Earnings Transcript
Via The Motley Fool · April 30, 2026
Exploring the top movers within the S&P500 index during today's session.chartmill.com
Via Chartmill · April 30, 2026
Why Eli Lilly Stock Just Poppedfool.com
GLP-1 drugs turned Lilly into a powerhouse. Now it's time to write the next chapter -- in cancer.
Via The Motley Fool · April 30, 2026
Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demandbenzinga.com
Eli Lilly beats Q1 estimates, lifts 2026 outlook as Mounjaro and Zepbound demand offsets pricing pressure and drives strong revenue growth.
Via Benzinga · April 30, 2026
These S&P500 stocks are gapping in today's sessionchartmill.com
Via Chartmill · April 30, 2026
Eli Lilly Obliterates Sales Forecasts By $2 Billion, Shares Surgeinvestors.com
Eli Lilly stock popped early Thursday after the drugmaker crushed first-quarter sales forecasts and hiked its 2026 guidance.
Via Investor's Business Daily · April 30, 2026
Discover the top S&P500 movers in Thursday's pre-market session.chartmill.com
Via Chartmill · April 30, 2026
Eli Lilly (NYSE:LLY) Delivers Strong Q1 CY2026 Numbers, Stock Soars
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 55.5% year on year to ...
Via StockStory · April 30, 2026
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.fool.com
The biotech's candidate may treat a great number of illnesses that have one thing in common.
Via The Motley Fool · April 30, 2026
Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analystsbenzinga.com
Eli Lilly & Co. (LLY) will release Q1 earnings on April 30. Analysts expect $6.79/share, up from $3.34/share last year. LLY down 2.6% on Wed.
Via Benzinga · April 30, 2026
Eli Lilly (LLY) Q1 Earnings: What To Expect
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results this Thursday before market hours. Here’s what to expect. Eli Lilly beat analyst...
Via StockStory · April 28, 2026